Apollo Biowellness, Inc., f/k/a Resonate Blends, Inc., Corporate Update
Rhea-AI Summary
Apollo Biowellness (OTC Pink: KOAN), formerly Resonate Blends, has announced several key business developments. The company has achieved full compliance with its filings and is preparing for OTCIQ listing. The company has successfully negotiated with creditors and is finalizing exclusive distribution agreements for its Evolutionary Biologics Brand across multiple regions.
Apollo is planning to launch a shelf-stabilized consumer cosmetic product through retail and e-commerce channels within the next few quarters. Management expects significant growth with international sales beginning in Q3 and Q4 2025.
Positive
- Company has achieved full compliance with filings and preparing for OTCIQ listing
- Successfully negotiated arrangements with creditors
- Finalizing exclusive distribution deals for North America with plans for international expansion
- New shelf-stabilized consumer cosmetic product launch planned for Q3 2025
Negative
- Company currently trades on OTC Pink market, indicating lower tier listing
- Previous creditor issues required negotiations
- Product launches and distribution deals are still pending, not finalized
North Bergen, New Jersey--(Newsfile Corp. - June 26, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC Pink: KOAN) (the "Company"), announces that it is fully compliant and is current in its filing. The Company is preparing to be listed on OTCIQ and is pleased to also announce that it has successfully made arrangements with various creditors to allow the Company to move forward and is now in the final stages to execute final exclusive distribution deals in North America, imminently and then later Europe, Middle East and Asia and Latin America on our Evolutionary Biologics Brand.
The Company is also planning, within the next couple of fiscal quarter, on launching a shelf stabilized consumer cosmetic direct to consumers through various retain outlets and e-commerce distribution channels.
James W. Zimbler, President, stated, "With these exciting new plans we expect to see enormous growth and will expect to be selling our products internationally starting in the third and fourth quarters. We are diligently working with various partners in developing the shelf stable consumer branded product, which we are excited to launch before the end of the third quarter and will be announced shortly."
About Apollo Biowellness, Inc. f/k/a Resonate Blends, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
www.evobiologics.com
jzimbler@emergenthealthcorp.com
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256855
FAQ
What is the current status of Apollo Biowellness (KOAN) compliance and listing?
What are Apollo Biowellness's (KOAN) expansion plans for 2025?
When will Apollo Biowellness (KOAN) launch its new consumer cosmetic product?
What is the relationship between Apollo Biowellness and Resonate Blends?
What progress has KOAN made with its creditors?
